Antimicrobial caps for medical connectors

Information

  • Patent Grant
  • 11357965
  • Patent Number
    11,357,965
  • Date Filed
    Monday, June 24, 2019
    5 years ago
  • Date Issued
    Tuesday, June 14, 2022
    2 years ago
Abstract
The present invention relates to a cap for a medical connector. More specifically, the present invention related to an antimicrobial cap for placement over a connector, wherein various features of the antimicrobial cap maintain the connector in an antiseptic state.
Description
BACKGROUND OF THE INVENTION

Infusion therapy generally involves the administration of a medication intravenously. When performing a typical infusion therapy, one or more infusion therapy device (e.g. tubing sets) are used. Oftentimes, during infusion therapy, the end of the tubing set is left exposed to non-sterile surfaces such as when a syringe is removed from a male Luer end of the tubing set. For example, when the end of the tubing set is exposed, the patient or nurse may touch the end, or the end may come in contact with non-sterile bedding, table, or floor surfaces.


Although it is required to clean the hub or needleless connector end of the tubing set, it is not required to clean the other end which is typically a male Luer. Disinfection caps are increasingly being used to disinfect the ends of infusion therapy devices such as needleless connectors, IV sets, or short extension tubing. Such caps generally include foam soaked with alcohol which contacts surfaces of the port when the cap is connected to the port. Various problems exist when using these caps. For example, the alcohol soaked foam only contacts exterior surfaces of the access port. Also, once a cap is placed on a port, the alcohol in the cap evaporates quickly. Further, use of alcohol often results in alcohol being forced into the IV line.


Further, some types of female Luer connectors trap liquids which are incapable of being effectively treated by conventional disinfection caps. For example, side ports on a catheter adapter are commonly used as a quick access for IV medications or fluid injection into an IV line, or into the patient's bloodstream, for quick effects, especially in emergency situations. The port may be accessed multiple times during the entire use of a catheter; sometimes in excess of seven days. Contaminated Luer access devices, such as a syringe, when connected to the port may transfer microorganisms the side wall and bottom of the side port. This may result in microorganism growth and colonization inside the port, which poses a risk of infection for the patient. Currently available disinfections caps are not able to effectively disinfect these surfaces.


Thus, while methods and systems currently exist for disinfecting needleless connectors, challenges still exist. Accordingly, it would be an improvement in the art to augment or replace current techniques with the systems and methods discussed herein.


BRIEF SUMMARY OF THE INVENTION

The present invention relates to a cap for a medical connector. More specifically, the present invention related to an antimicrobial cap for placement over a connector, wherein various features of the antimicrobial cap maintain the connector in an antiseptic state.


Some implementations of the present invention provide an antimicrobial cap having an inner surface on which is disposed a dry, non-bonded antimicrobial material. Upon exposure to a residual fluid, the dry, non-bonded antimicrobial material is quickly dissolved, thereby forming an antimicrobial solution within the closed volume of the cap. The antimicrobial solution contacts the inner surface of the cap and the outer surfaces of a connector inserted within the interior of the cap.


Other implementations of the present invention provide various clip features on the outer surface of an antimicrobial cap, wherein the clip feature allow the cap to be attached to a section of IV tubing, or an IV pole to prevent the cap from contacting an undesired surface, such as the ground. Various structures are further provided for storing and dispensing the antimicrobial caps to a clinician.


Some implementations of the present invention further comprise an antimicrobial cap having an antimicrobial plug. The antimicrobial plug extends outwardly from the inner, base surface of the cap and extends into an interior volume of a connector having an interior space into which the plug may extend. The antimicrobial plug may comprise various shapes and configurations to maximize surface area without compromising the function of the cap and/or the connector.


In some instances, an antimicrobial cap is provided having a removable/disposable antimicrobial plug. The removable plug is inserted into the cap via a hole provided in the base of the cap, opposite the opening of the cap. The plug may be inserted, used, and then removed to maintain adequate antimicrobial effect.


Some implementations of the instant invention comprise an antimicrobial growth material that is attached to the inner surface of the cap's base. The growth material comprises an antimicrobial agent or coating that is eluted from the material when contacted by a residual fluid. The growth material is dehydrated and swells or grows when exposed to a liquid.


Further, some implementations of the instant invention comprise a cap having an inner surface on which is disposed an antimicrobial lubricant. The antimicrobial lubricant is transferred to the outer and inner surfaces of a connector when the cap is placed thereon. Upon removal of the cap, the antimicrobial lubricant remains on the cap and connector surfaces, thereby imparting an antimicrobial effect.


This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.


Additional features and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by the practice of the invention. The features and advantages of the invention may be realized and obtained by means of the instruments and combinations particularly pointed out in the appended claims. These and other features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.





BRIEF DESCRIPTION OF THE DRAWINGS

In order to describe the manner in which the above-recited and other advantages and features of the invention can be obtained, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. Understanding that these drawings depict only typical embodiments of the invention and are not therefore to be considered to be limiting of its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:



FIG. 1 shows a cross-section view of an antimicrobial cap in accordance with a representative embodiment of the present invention;



FIG. 2 shows a cross-section view of an antimicrobial cap and a perspective view of a connector inserted therein in accordance with a representative embodiment of the present invention.



FIG. 3, shown in parts A-C, shows perspective views of various clip features in accordance with various representative embodiment of the present invention.



FIG. 4, shown in parts A-C, shows perspective views of various storage and distributions methods and devices in accordance with various representative embodiments of the present invention.



FIG. 5, shown in parts A and B, shows cross-section views of an antimicrobial cap having an antimicrobial plug in accordance with a representative embodiment of the present invention.



FIG. 6, shown in parts A and B, shows a cross-section view of a curved antimicrobial plug in accordance with a representative embodiment of the present invention.



FIG. 7, shown in parts A and B, shows a cross-section view of an antimicrobial plug having a terminal end disc in accordance with a representative embodiment of the present invention.



FIG. 8 shows a cross-section view of an antimicrobial plug having a three-dimensional terminal end shape that is the same as the internal geometry of the side port in accordance with a representative embodiment of the present invention.



FIG. 9, shown in parts A-D, shows various views of a removable antimicrobial plug in accordance with various representative embodiments of the present invention.



FIG. 10, shown in parts A and B, shows cross-section views of an antimicrobial growing material in accordance with a representative embodiment of the present invention.



FIG. 11, shown in parts A-C, shows cross-section views of a cap having an antimicrobial lubricant applied to the inner surface of the cap in accordance with a representative embodiment of the present invention.





DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a cap for a medical connector. More specifically, the present invention related to an antimicrobial cap for placement over a connector, wherein various features of the antimicrobial cap maintain the connector in an antiseptic state.


As used herein the term “connector” is understood to include any structure that is part of an intravenous device that is capable of making a connection with a secondary intravenous device. Non-limiting examples of connectors in accordance with the present invention include needleless connectors, male Luer connectors, female Luer connectors, side port valves, y-port valves, port valves, and other similar structures.


Referring now to FIG. 1, an antimicrobial cap 10 is shown. Antimicrobial cap 10 generally comprises a polymer material that is safe for use with fluid and chemicals common to infusion procedures. For example, in some instances cap 10 comprises a poly vinyl chloride material. Cap 10 comprises an opening 12 having a diameter sufficient to receive a connector 30. In some instances, connector 30 comprises a positive surface that may be inserted through opening 12 of cap 10. For example, in some instances connector 30 comprises a male Luer connector. In other instances connector 30 comprises a syringe tip. Further, in some instances connector 30 comprises a side port or y-port of a catheter adapter. In other instances connector 30 comprises a catheter adapter, a section of IV tubing, or a catheter.


In some embodiments, cap 10 receives connector 30 via a threaded connection. For example, in some instances cap 10 comprises a set of internal or external threads that are threadedly engaged by a complementary set of threads located on the connector. In other instances, cap 10 receives connector 30 via a friction or interference fit.


Antimicrobial cap 10 further comprises an inner surface 14 defining a volume sufficient to receive connector 30. Inner surface 14 is generally tubular, however in some instances inner surface 14 tapers inwardly from opening 12 to the cap's base 16. Inner surface 14 may include any geometry or shape as may be desired.


The volume of cap 10 comprises the interior space of cap 10 extending from opening 12 to base 16. The volume is generally selected to admit placement of connector 30 within cap 10 for the purpose of maintaining cap 10 in an antiseptic condition. Accordingly, antimicrobial cap 10 further comprises a quantity of antimicrobial material 20 applied to inner surface 14. Antimicrobial material 20 may comprise any type or form of antimicrobial material that is safe for use in accordance with the teachings of the present invention. For example, in some instances antimicrobial material 20 is selected from a group consisting of chlorhexidine diacetate, chlorhexidine gluconate, alexidine, silver sulfadiazine, silver acetate, silver citrate hydrate, cetrimide, cetyl pyridium chloride, benzalkonium chloride, o-phthalaldehyde, and silver element.


In some embodiments, antimicrobial material 20 comprises a dry, non-bonded coating that is applied to inner surface 14 by a known method. For instance, in some embodiments antimicrobial material 20 is applied to inner surface 14 by spraying, dipping or brushing. In other instances, antimicrobial material 20 comprises a UV cured polymer matrix in which an antimicrobial agent is uniformly dispersed. The antimicrobial agent is not chemically bound to the polymer matrix, and therefore is capable of being eluted out of the matrix when the matrix is exposed to, or wetted by a residual fluid.


When cap 10 is placed onto connector 30, connector 30 reduces the volume of cap 10. Once secured together, connector 30 and antimicrobial cap 10 form a closed volume between the interconnected devices. Upon exposure to a residual fluid 32 from connector 30, the dry, non-bonded antimicrobial material 20 is rapidly dissolved by residual fluid 32, thereby forming an antimicrobial solution with the residual fluid 32 within the closed volume, as shown in FIG. 2. The antimicrobial solution is contained within the closed volume and is exposed to all of the surfaces of needleless adapter 30 and inner surface 14 positioned within the closed volume.


As discussed above, in some instances antimicrobial material 20 comprises a UV cured, hydrophilic polymer material that forms a matrix comprising a plurality of microscopic interstices in which an antimicrobial agent is evenly dispersed (not shown). Upon exposure to residual fluid 32, the polymer matrix is softened and penetrated by the residual fluid. The antimicrobial agent within the polymer matrix is eluted out of the matrix and into the residual fluid to form an antimicrobial solution have a desired final concentration within the closed volume. Examples of suitable polymer materials are provided in U.S. patent application Ser. Nos. 12/397,760, 11/829,010, 12/476,997, 12/490,235, and 12/831,880, each of which is incorporated herein in their entireties.


Generally, a quantity or amount of antimicrobial material 20 is applied to inner surface so that upon being dissolved in residual fluid 32 within the closed volume, an antimicrobial solution is provided having a minimum concentration required to have sufficient antimicrobial efficacy within the closed volume. In some instances, a predetermined quantity or amount of antimicrobial material 20 is applied to inner surface 14 to provide a final concentration from approximately 0.005% w/w to approximately 25% w/w. Thus, the quantity or amount of antimicrobial material 20 is determined based upon the calculated closed volume of antimicrobial cap 10 and connector 30.


For example, if the volume of antimicrobial cap 10 is 1 cm3, and the volume of the portion of connector 30 that is inserted into cap 10 is 0.75 cm3, then the calculated closed volume of antimicrobial cap 10 is 0.25 cm3. Thus, the maximum possible volume of residual fluid 32 within the closed volume is 0.25 cm3. Accordingly, to achieve a final, desired concentration of antimicrobial material within the antimicrobial solution from approximately 0.005% w/w to approximately 25% w/w (within the closed volume), approximately 12.6 μg to approximately 83.3 mg of antimicrobial material 20 will need to be applied to inner surface 14.


Residual fluid 32 may comprise any fluid or combination of fluids common to infusion therapy procedures. For example, in some embodiments residual fluid 32 comprises blood, a medicament, water, saline, urine, or combinations thereof. In some instances, a residual fluid 32 leaks into antimicrobial cap 10 after connector 30 has been inserted into cap 10. In other instance, a residual fluid 32 is present on connector 30 prior to being inserted into cap 10. Further, in some instances a residual fluid 32 is present in antimicrobial cap 10 prior to connector 30 being inserted therein.


Following use of antimicrobial cap 10, cap 10 is removed from connector 30 and is disposed. In some instances, antimicrobial cap 10 is reused multiple times prior to being disposed. For example, in some instances cap 10 is applied to connector 30 after connector 30 is removed from a separate connector (not shown). Prior to reconnecting connector 30 to the separate connector, antimicrobial cap 10 is again removed from connector 30, and reapplied following removal of connector 30 from the separate connector.


In some instances, the exterior 18 of antimicrobial cap 10 further comprises a clip 40 having a surface 42 for receiving at least one of an IV line, and an IV pole to maintain a desired position of antimicrobial cap 10, as shown in FIGS. 3A-3C. In some instances, clip 40 comprises a pair of opposed arms forming an aperture 44 having a diameter sufficient to receive the outer diameter of a section of IV tubing 50, as shown in FIG. 3B. In other instances, clip 40 comprises a single hook 60 having a hooked surface for compatibly receiving an IV pole 52, as shown in FIG. 3C. Thus, in some embodiments antimicrobial cap 10 is coupled to a connector 30 and then coupled to a section of IV tubing 50 or an IV pole 52 via clip 40 to prevent undesired contact with a floor or other undesirable surface.


Referring now to FIG. 4, the present invention further comprises various devices for storing and dispensing antimicrobial cap 10. For example, in some instances a disposable strip 70 is provided having an elongated surface 72 on which the base 16 surfaces of multiple caps 10 is temporarily adhered with a weak adhesive, as shown in FIG. 4A. Since antimicrobial material 20 is provided in a dry form, openings 12 may be oriented outwardly from surface 72 without requiring a foil or polymer cover. Strip 70 further comprises a hole 74 designed to receive a hook portion of an IV pole, whereby to suspend strip 70 in a convenient location for a clinician.


In other instances, the exterior surfaces 18 of antimicrobial caps 10 are tapered inwardly from opening 12 to base 16, wherein the diameter of base 16 is less than the diameter of opening 12, as shown in FIG. 4B. Thus, base 16 may be fitted into opening 12 of an adjacent cap 10 by interference fit to form a stacked configuration. Again, the dry form of antimicrobial material 20 does not require a foil or polymer cover for openings 12, thereby allowing the stacked configuration for storage and dispensing purposes.


Further, in some instances a caddy 80 is provided having opposing surfaces 82 on which the base surfaces 16 of multiple caps 10 are temporarily adhered with a weak adhesive, as shown in FIG. 4C. Since antimicrobial material 20 is provided in a dry form, openings 12 may be oriented outwardly from surfaces 82 without requiring covers for opening 12. Caddy 80 further comprises a hole 84 designed to receive a hook portion 54 of an IV pole, whereby to suspend caddy 80 in a convenient location for a clinician. Caddy 80 further comprises a clip 40 having a surface 42 and aperture 44 for receiving a section of IV tubing.


Referring now generally to FIGS. 5-11C, in some instances antimicrobial cap 100 is hingedly coupled to a catheter adapter 120 and configured to provide a physical barrier for a connector comprising a side port 130. Although shown as being hingedly integrated onto a catheter adapter, the features of antimicrobial cap 100 discussed in connection with these embodiments may be implemented into any style or form of antimicrobial cap configured to receive any type or style of connector.


With specific reference to FIGS. 5A and 5B, in some instances antimicrobial cap 100 comprises an opening 102 having a diameter sufficient to receive side port 130. Cap 100 further comprises an inner surface 104 defining a volume sufficient to receive side port 130.


Side port 130 comprises an opening or aperture 132, an internal volume 134, and a bottom 136. In some instances, internal volume 134 may further comprise a unique internal geometry, as discussed below. Side port 130 further comprises a port valve 138 that forms a defeatable seal between side port 130 and an interior lumen of catheter adapter 120. Upon injecting a fluid into side port 130, port valve 138 is temporarily defeated to break the seal and permit the injected fluid to bypass port valve 138 and enter the interior lumen of catheter adapter 120. Following the injection, a small aliquot of residual fluid is typically left in internal volume 134, and may be susceptible to microbial contamination. This residual fluid typically pools and gathers at the bottom 136 of side port 130 and contacts the outer surface of port valve 138. However, larger volumes of residual fluid may contact additional surfaces of internal volume 134, and may even fill or substantially fill internal volume 134.


Antimicrobial cap 100 further comprises an antimicrobial plug 110. Antimicrobial plug 110 generally comprises an antimicrobial material or coating that is readily dissolved or eluted when plug 110 contacts a residual fluid in internal volume 134. In some instances, antimicrobial plug 110 comprises a UV cured, hydrophilic material in which is evenly dispersed an antimicrobial agent, as described above. In other instances, plug 110 is comprised of a solid antimicrobial material. In other instances, plug 110 comprises a polymer tube having an antimicrobial coating.


Antimicrobial plug 110 may comprise any form or shape that is compatible with the teachings of the present invention. For example, in some instances plug 110 comprises a tubular shape. In other instances plug 110 comprises a rod. Further, in some instances antimicrobial plug 110 comprises a non-linear shape or design, as shown and discussed in connection with FIGS. 8B-9, below.


Antimicrobial plug 110 comprises a proximal end 112 that is attached to base 106 of cap 100, and further comprises a distal end 114 that extends outwardly from base 106. Plug 110 comprises a length and diameter sufficient to be inserted through aperture 132 and positioned within internal volume 134 such that distal end 114 is positioned in proximity with bottom 136 when cap 100 is coupled to side port 130, as shown in FIG. 5B.


The length and diameter of plug 110 is selected to maximize the surface area of plug 110 without compromising the ability of cap 100 to be hingedly closed over side port 130. In some instances plug 110 comprises an outer diameter of approximately 0.076 inches and a functional height of approximately 0.338 inches.


In some instances it may be desirable to increase the surface area of antimicrobial plug 110 while still maintaining the functionality of the hinged connection. Accordingly, in some embodiments antimicrobial plug 110 is curved, as shown in FIGS. 6A and 6B. The curved configuration of plug 110 increases the overall length of plug 110 yet prevents contact between distal end 114 and aperture 132 upon hingedly closing cap 100 onto side port 130. Thus, the overall surface area of plug 110 is increased without disturbing the normal function of the hinged cap.


In other instances, distal end 114 further comprises a disc 116 having an increased diameter that is slightly less than the diameter of bottom 136, as shown in FIGS. 7A and 7B. Disc 116 increases the overall surface area of plug 110 without disturbing the normal function of the hinged cap. In some instance, disc 116 is positioned within bottom 136 when cap 100 is seated onto side port 130. Thus, the increased surface area of disc 116 is positioned within the location of internal volume 134 that is most likely to contain residual fluid. In some instances, the process of advancing disc 116 into bottom 136 displaces residual fluid from bottom 136, whereby the majority of space at bottom 136 is occupied by the antimicrobial disc 116.


In some embodiments, internal volume 134 comprises a unique, internal geometry 140 having various surfaces, as shown in FIG. 8. Maximum antimicrobial effects may thus be achieved by shaping distal end 114 to have the same geometry as internal geometry 140. Thus, distal end 114 achieves maximum surface contact with internal geometry 140, thereby imparting maximum antimicrobial effect to internal volume 134.


Some implementations of the present invention further comprise a cap 200 having a hole 220 in the cap's base 216, as shown in FIGS. 9A and 9B. Hole 220 comprises a diameter configured to receive a removable and/or disposable antimicrobial plug 210. Plug 210 comprises materials and characteristics similar to the other antimicrobial components and devices previously described herein.


Cap 200 is assembled by inserting distal end 214 into and through hole 220 until proximal end 212 is fully seated into recess 217 of base 216, as shown in FIG. 9B. In some instances, the shaft portion of antimicrobial plug 210 comprises a diameter that is slightly larger than the diameter of hole 220, thereby facilitating a fluid-tight, interference fit between the two components. Antimicrobial plug 210 may subsequently be removed from cap 200 and replaced with a new plug once the antimicrobial properties of the initial plug 210 are exhausted. In other instances, antimicrobial plug 210 is replaced at a controlled frequency for maintained antimicrobial effects.


In some embodiments, multiple antimicrobial plugs are provided from which a user may select and insert into hole 220. For example, in some instances a plurality of plugs are provided, wherein each plug comprises a unique or different antimicrobial agent. Antimicrobial plug 210 may also comprise various non-linear shapes, such as a spiral shape or wavy shape, as demonstrated in FIGS. 9C and 9D. These shapes increase the overall surface area of plug 210 without disturbing the normal function of cap 200, as discussed previously.


Some implementations of the present invention further comprise a cap 300 comprising a base surface 316 on which is providing a dehydrated antimicrobial material 380, as shown in FIG. 10A. The dehydrated antimicrobial material 380 comprises a material that swells and grows when exposed to residual fluids located within the internal volume of side port 130. For example, in some instances dehydrated antimicrobial material 380 comprises an open-cell, non-woven sponge material. In other instances dehydrated antimicrobial material 380 comprises a hydrogel.


Material 380 further comprises an antimicrobial agent 320, or an antimicrobial coating comprising an antimicrobial agent that is dissolved or eluted when material 380 is exposed to residual liquid 32, thereby swelling or undergoing an expansive growth, as shown in FIG. 10B. In some instances, material 380 resumes its original conformation upon removal of residual liquid 32. In other instances, a change in the size of material 380 indicates the presence of residual fluid 32, thereby alerting a clinician to replace cap 300 with a new cap.


Further, in some instances the inner surface 404 of cap 400 comprises an antimicrobial lubricant 450, as shown in FIGS. 11A-11C. Antimicrobial lubricant 450 comprises a viscous or semi-viscous lube or gel having an antimicrobial agent that kills microbes that come in contact with the lubricant 450. In some instances, antimicrobial lubricant 450 comprises a mixture of chlorhexidine acetate, or chlorhexidine gluconate, and silicone.


A portion of antimicrobial lubricant 450 is transferred to the outer and inner surfaces of side port 130 as cap 400 is placed onto side port 130, as shown in FIG. 11B. Upon removal of cap 400 from side port 130, residual antimicrobial lubricant 450 remains on the inner surfaces of cap 400, and on the inner and outer surfaces of side port 130, as shown in FIG. 11C.


One having skill in the art will appreciate that the various other embodiments of the present invention may similarly be coated with an antimicrobial lubricant, thereby further adding a contact kill effect to the device. Thus, the features of the various embodiments of the present invention may be interchangeably implemented to provide a wide variety of antimicrobial caps and other devices.


Various embodiments of the present invention may be manufactured according to know methods and procedures. In some instances, an antimicrobial component is comprises of an antimicrobial material. In other instances, an antimicrobial component is extruded or molded of base polymer materials that have good bond strength to an antimicrobial material or agent, such as polycarbonate, copolyester, ABS, PVC, and polyurethane. The base polymer structure may be coated with an adhesive-based antimicrobial material, which may have elution characteristics. In some instances, the topology and dimensions of the base polymer structure are optimized for microbiology efficacy, lasting elution profiles, and assembly geometry constraints.


Various antimicrobial components of the instant invention may be casted or molded directly of antimicrobial material. In some instances, the antimicrobial component is casted in plastic and subsequently coated with an antimicrobial material. In some embodiments, an antimicrobial component is grown directly onto another component of the device. For example, in some instances an antimicrobial plug is grown directly from the inner or base surface of the cap. This is done by first placing a peel-away sleeve on the base surface of the cap. The antimicrobial material is deposited into the lumen formed by the sleeve. After curing is complete, the sleeve is peeled away, thereby revealing the plug on the base surface of the cap.


In other instances, various components of the device are joined together via an adhesive or epoxy. For example, in some instances an antimicrobial plug is initially casted or molded, and then coated with an antimicrobial coating or material. The coated plug is then adhered to the base surface of the cap by an epoxy. For the disc-end antimicrobial plugs, the disc and the rod or tube may be cast as a whole piece, or may be case or molded separately and then subsequently bonded together.


Antimicrobial components and coatings of the instant invention may be comprised of one or multiple antimicrobial agents in a polymer matrix. The polymer matrix may be adhesive-based, with a preference to acrylate- or cyanoacrylate-based adhesives for good bond strength and fast elution rates. Solvents may be added to increase bonding. Non-limiting examples of suitable antimicrobial material compositions are provided in United States Published Patent Application Nos. 2010/0137472, and 2010/0135949, each of which is incorporated herein by reference in their entireties.


The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims
  • 1. An antimicrobial cap device for a medical connector, the medical connector having an upper aperture, a bottom, and an internal volume, the antimicrobial cap device comprising: a first end configured to secure the antimicrobial cap device to the medical connector, the first end having an opening sized to receive at least the upper aperture of the medical connector;a base opposite the first end;a sidewall connecting the base to the first end, an inner surface of the sidewall defining a volume sufficient to receive at least the upper aperture of the medical connector, wherein while the antimicrobial cap device is secured to the medical connector, the antimicrobial cap device is configured to form with a portion of the medical connector a closed volume comprising the internal volume of the medical connector; andan antimicrobial plug having a proximal end attached to the base and a distal end disposed outwardly therefrom, the antimicrobial plug comprising a spiral shape between the proximal end and the distal end, wherein the spiral shape is a non-luer shape.
  • 2. The antimicrobial cap device of claim 1, wherein the antimicrobial plug comprises an antimicrobial material, wherein the antimicrobial material is selected from a group consisting of chlorhexidine diacetate, chlorhexidine gluconate, alexidine, silver sulfadiazine, silver acetate, silver citrate hydrate, cetrimide, cetyl pyridium chloride, benzalkonium chloride, o-phthalaldehyde, and silver element.
  • 3. The antimicrobial cap device of claim 1, wherein the base comprises a hole, wherein the distal end of the antimicrobial plug is inserted through the hole and the proximal end of the antimicrobial plug seals the hole.
  • 4. The antimicrobial cap device of claim 1, wherein the antimicrobial plug comprises an antimicrobial material.
  • 5. The antimicrobial cap device of claim 1, wherein the antimicrobial plug comprises a polymer matrix in which is evenly dispersed an antimicrobial agent.
  • 6. The antimicrobial cap device of claim 5, wherein the antimicrobial agent is configured to elute from the polymer matrix when the antimicrobial plug is contacted by fluid.
  • 7. The antimicrobial cap device of claim 1, wherein the spiral shape increases a surface area of the antimicrobial plug.
  • 8. An antimicrobial cap device for a medical connector, the medical connector having an upper aperture, a bottom, and an internal volume, the antimicrobial cap device comprising: a first end configured to secure the antimicrobial cap device to the medical connector, the first end having an opening sized to receive at least the upper aperture of the medical connector;a base opposite the first end;a sidewall connecting the base to the first end, an inner surface of the sidewall defining a volume sufficient to receive at least the upper aperture of the medical connector, wherein while the antimicrobial cap device is secured to the medical connector, the antimicrobial cap device is configured to form with a portion of the medical connector a closed volume comprising the internal volume of the medical connector; andan antimicrobial plug having a proximal end attached to the base and a distal end disposed outwardly therefrom, the antimicrobial plug comprising a spiral shape between the proximal end and the distal end and an antimicrobial growth material, wherein the antimicrobial growth material is dehydrated and swells or grows when exposed to a liquid.
  • 9. The antimicrobial cap device of claim 8, wherein the antimicrobial plug comprises an antimicrobial material, wherein the antimicrobial material is selected from a group consisting of chlorhexidine diacetate, chlorhexidine gluconate, alexidine, silver sulfadiazine, silver acetate, silver citrate hydrate, cetrimide, cetyl pyridium chloride, benzalkonium chloride, o-phthalaldehyde, and silver element.
  • 10. The antimicrobial cap device of claim 8, wherein the base comprises a hole, wherein the distal end of the antimicrobial plug is inserted through the hole and the proximal end of the antimicrobial plug seals the hole.
  • 11. The antimicrobial cap device of claim 8, wherein the antimicrobial plug comprises an antimicrobial material.
  • 12. The antimicrobial cap device of claim 8, wherein the antimicrobial plug comprises a polymer matrix in which is evenly dispersed an antimicrobial agent.
  • 13. The antimicrobial cap device of claim 12, wherein the antimicrobial agent is configured to elute from the polymer matrix when the antimicrobial plug is contacted by fluid.
  • 14. An antimicrobial cap device for a medical connector, the medical connector having an upper aperture, a bottom, and an internal volume, the antimicrobial cap device comprising: a first end configured to secure the antimicrobial cap device to the medical connector, the first end having an opening sized to receive at least the upper aperture of the medical connector;a base opposite the first end;a sidewall connecting the base to the first end, an inner surface of the sidewall defining a volume sufficient to receive at least the upper aperture of the medical connector, wherein while the antimicrobial cap device is secured to the medical connector, the antimicrobial cap device is configured to form with a portion of the medical connector a closed volume comprising the internal volume of the medical connector; andan antimicrobial plug having a proximal end attached to the base and a distal end disposed outwardly therefrom, the antimicrobial plug comprising a spiral shape between the proximal end and the distal end, the proximal end having a first width and the distal end having a second width, wherein the first width is greater than the second width, wherein the antimicrobial plug further comprises a solid body between the distal end and the proximal end.
  • 15. The antimicrobial cap device of claim 14, wherein the antimicrobial plug comprises an antimicrobial material, wherein the antimicrobial material is selected from a group consisting of chlorhexidine diacetate, chlorhexidine gluconate, alexidine, silver sulfadiazine, silver acetate, silver citrate hydrate, cetrimide, cetyl pyridium chloride, benzalkonium chloride, o-phthalaldehyde, and silver element.
  • 16. The antimicrobial cap device of claim 14, wherein the base comprises a hole, wherein the distal end of the antimicrobial plug is inserted through the hole and the proximal end of the antimicrobial plug seals the hole.
  • 17. The antimicrobial cap device of claim 14, wherein the antimicrobial plug comprises an antimicrobial material.
  • 18. The antimicrobial cap device of claim 17, wherein the antimicrobial material is dehydrated and swells or grows when exposed to a liquid.
  • 19. The antimicrobial cap device of claim 14, wherein the antimicrobial plug comprises a polymer matrix, wherein an antimicrobial agent is evenly dispersed in the polymer matrix.
  • 20. The antimicrobial cap device of claim 19, wherein the antimicrobial agent is configured to elute from the polymer matrix when the antimicrobial plug is contacted by fluid.
RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/260,027, filed Apr. 23, 2014, and titled ANTIMICROBIAL CAPS FOR MEDICAL CONNECTORS, which is incorporated herein in its entirety.

US Referenced Citations (420)
Number Name Date Kind
1844023 Terry Feb 1932 A
3223629 Loeffler Dec 1965 A
3352531 Kilmarx Nov 1967 A
3598127 Wepsic Aug 1971 A
3695921 Shepherd et al. Oct 1972 A
3867937 Schwarts Feb 1975 A
3986508 Barrington Oct 1976 A
4068660 Beck Jan 1978 A
4170996 Wu Oct 1979 A
4280500 Ono Jul 1981 A
4334551 Pfister Jun 1982 A
4339336 Hammond et al. Jul 1982 A
4387879 Tauschinski Jun 1983 A
4449693 Gereg May 1984 A
4469483 Becker et al. Sep 1984 A
4512766 Vaillancourt Apr 1985 A
4584192 Dell et al. Apr 1986 A
4585435 Vaillancourt Apr 1986 A
4592920 Murtfeldt Jun 1986 A
4603152 Laurin et al. Jul 1986 A
4610674 Suzuki et al. Sep 1986 A
4629743 Michl Dec 1986 A
4629746 Michi Dec 1986 A
4642126 Zador et al. Feb 1987 A
4676782 Yamamoto et al. Jun 1987 A
4677143 Laurin et al. Jun 1987 A
4716032 Westfall et al. Dec 1987 A
4723948 Clark et al. Feb 1988 A
4758225 Cox et al. Jul 1988 A
4781703 Walker et al. Nov 1988 A
4798594 Hillstead Jan 1989 A
4805933 Swisher Feb 1989 A
4838873 Landskron et al. Jun 1989 A
4842591 Luther Jun 1989 A
4846812 Walker et al. Jul 1989 A
4874377 Newgard et al. Oct 1989 A
4880414 Whipple Nov 1989 A
4895566 Lee Jan 1990 A
4897427 Bamavon et al. Jan 1990 A
4915934 Tomlinson Apr 1990 A
4917668 Haindl Apr 1990 A
4925668 Khan et al. May 1990 A
4933178 Capelli Jun 1990 A
4935010 Cox et al. Jun 1990 A
4950257 Hibbs et al. Aug 1990 A
4955890 Yamamoto et al. Sep 1990 A
4976697 Walder et al. Dec 1990 A
4985399 Matsuda et al. Jan 1991 A
4990357 Karakelle et al. Feb 1991 A
5019096 Fox, Jr. et al. May 1991 A
5023082 Friedman et al. Jun 1991 A
5030665 Lee Jul 1991 A
5041097 Johnson Aug 1991 A
5053014 Van Heugten Oct 1991 A
5062836 Wendell Nov 1991 A
5064416 Newgard et al. Nov 1991 A
5077352 Elton Dec 1991 A
5078703 Bryant Jan 1992 A
5084023 Lemieux Jan 1992 A
5085645 Purdy et al. Feb 1992 A
5098405 Peterson et al. Mar 1992 A
5098410 Kerby et al. Mar 1992 A
5108374 Lemieux Apr 1992 A
5127905 Lemieux Jul 1992 A
5129887 Euteneuer et al. Jul 1992 A
5154703 Bonaldo Oct 1992 A
5156596 Balbierz et al. Oct 1992 A
5167647 Wijkamp et al. Dec 1992 A
5217493 Raad et al. Jun 1993 A
5226898 Gross Jul 1993 A
5234410 Graham et al. Aug 1993 A
5242425 White et al. Sep 1993 A
5256145 Atkinson et al. Oct 1993 A
5290246 Yamamoto et al. Mar 1994 A
5295969 Fischell et al. Mar 1994 A
5330435 Vaillancourt Jul 1994 A
5330449 Prichard et al. Jul 1994 A
5350363 Goode et al. Sep 1994 A
5352205 Dales et al. Oct 1994 A
5357636 Dresdner, Jr. et al. Oct 1994 A
5366505 Farber Nov 1994 A
5380301 Prichard et al. Jan 1995 A
5405323 Rogers et al. Apr 1995 A
5405338 Kranys Apr 1995 A
5456675 Wolbring et al. Oct 1995 A
5456948 Mathisen et al. Oct 1995 A
5458640 Gerrone Oct 1995 A
5470319 Mayer Nov 1995 A
5487728 Vaillancourt Jan 1996 A
5512199 Khan et al. Apr 1996 A
5520666 Choudhury et al. May 1996 A
5536258 Folden Jul 1996 A
5540661 Tomisaka et al. Jul 1996 A
5547662 Khan et al. Aug 1996 A
5549566 Elias et al. Aug 1996 A
5549577 Siegel et al. Aug 1996 A
5575769 Vaillancourt Nov 1996 A
5589120 Khan et al. Dec 1996 A
5613663 Schmidt et al. Mar 1997 A
5616338 Fox, Jr. et al. Apr 1997 A
5620434 Brony Apr 1997 A
5629006 Hoang et al. May 1997 A
5638812 Turner Jun 1997 A
5651772 Arnett Jul 1997 A
5653695 Hopkins et al. Aug 1997 A
5657963 Hinchliffe et al. Aug 1997 A
5658253 Piontek et al. Aug 1997 A
5676656 Brimhall Oct 1997 A
5688747 Khan et al. Nov 1997 A
5697915 Lynn Dec 1997 A
5698229 Ohsumi et al. Dec 1997 A
5712229 Hopkins et al. Jan 1998 A
5716406 Farber Feb 1998 A
5718678 Fleming, III Feb 1998 A
5738144 Rogers Apr 1998 A
5749861 Guala et al. May 1998 A
5763412 Khan et al. Jun 1998 A
5773487 Sokoi Jun 1998 A
5806831 Paradis Sep 1998 A
5810768 Lopez Sep 1998 A
5817069 Arnett Oct 1998 A
5827239 Dillon et al. Oct 1998 A
5830196 Hicks Nov 1998 A
5830401 Prichard et al. Nov 1998 A
5833674 Trumbull et al. Nov 1998 A
5843046 Motisi et al. Dec 1998 A
5861440 Gohla et al. Jan 1999 A
5911710 Barry et al. Jun 1999 A
5944712 Frassica et al. Aug 1999 A
5951519 Utterberg Sep 1999 A
5954698 Pike Sep 1999 A
5957898 Jepson et al. Sep 1999 A
5967490 Pike Oct 1999 A
6039302 Cote, Sr. et al. Mar 2000 A
6046143 Khan et al. Apr 2000 A
6050978 Orr et al. Apr 2000 A
6051609 Yu et al. Apr 2000 A
6068622 Sater et al. May 2000 A
6074379 Prichard Jun 2000 A
6077244 Botich et al. Jun 2000 A
6082490 Rowland Jul 2000 A
6102890 Stivland et al. Aug 2000 A
6117108 Woehr et al. Sep 2000 A
6120784 Snyder, Jr. Sep 2000 A
6127320 van Ooij et al. Oct 2000 A
6156054 Zadno-Azizi et al. Dec 2000 A
6165168 Russo Dec 2000 A
6171287 Lynn et al. Jan 2001 B1
6217566 Ju et al. Apr 2001 B1
6228073 Noone et al. May 2001 B1
6242526 Siddiqui et al. Jun 2001 B1
6245098 Feeser et al. Jun 2001 B1
6248811 Ottersbach et al. Jun 2001 B1
6273404 Holman et al. Aug 2001 B1
6273869 Vaillancourt Aug 2001 B1
6322847 Zhong et al. Nov 2001 B1
6326417 Jia Dec 2001 B1
6332874 Eliasen et al. Dec 2001 B1
6337357 Fukunishi et al. Jan 2002 B1
6344218 Dodd et al. Feb 2002 B1
6353041 Qian Mar 2002 B1
6387075 Stivland et al. May 2002 B1
6394983 Mayoral May 2002 B1
6413539 Shalaby Jul 2002 B1
6426373 Stange et al. Jul 2002 B1
6475434 Darouiche Nov 2002 B1
6485473 Lynn Nov 2002 B1
6488942 Ingemann Dec 2002 B1
6492445 Siddiqui et al. Dec 2002 B2
6503353 Peterson et al. Jan 2003 B1
6511462 Itou et al. Jan 2003 B1
6544214 Utterberg Apr 2003 B1
6575958 Happ et al. Jun 2003 B1
6575960 Becker et al. Jun 2003 B2
6576633 Young et al. Jun 2003 B1
6579221 Peterson Jun 2003 B1
6579539 Lawson et al. Jun 2003 B2
6595981 Huet Jul 2003 B2
6663614 Carter Dec 2003 B1
6699221 Vaillancourt Mar 2004 B2
6719726 Meng et al. Apr 2004 B2
6719991 Darouiche et al. Apr 2004 B2
6723350 Burrell et al. Apr 2004 B2
6740063 Lynn May 2004 B2
6808161 Hishikawa Oct 2004 B1
6843784 Modak et al. Jan 2005 B2
6846846 Modak et al. Jan 2005 B2
6861060 Luriya et al. Mar 2005 B1
6883778 Newton et al. Apr 2005 B1
6887270 Miller et al. May 2005 B2
6893456 Lumauig May 2005 B2
6896889 Chevalier et al. May 2005 B2
7008404 Nakajima Mar 2006 B2
7074839 Fansler et al. Jul 2006 B2
7098256 Ong et al. Aug 2006 B2
7115183 Larson et al. Oct 2006 B2
7179849 Terry Feb 2007 B2
7198800 Ko Apr 2007 B1
7232428 Inukai et al. Jun 2007 B1
7232540 Gould et al. Jun 2007 B2
7261925 Nesbit Aug 2007 B2
7268165 Greten et al. Sep 2007 B2
7347839 Hiejima Mar 2008 B2
7374798 Choo et al. May 2008 B2
7396346 Nakajima Jul 2008 B2
7407707 Gould et al. Aug 2008 B2
7462401 Halfyard et al. Dec 2008 B2
7470254 Basta et al. Dec 2008 B2
7494339 Dias et al. Feb 2009 B2
7498367 Qian Mar 2009 B2
7514477 Klare et al. Apr 2009 B2
7608082 Cuevas et al. Oct 2009 B2
7682340 Funamura et al. Mar 2010 B2
7704935 Davis et al. Apr 2010 B1
7736339 Woehr et al. Jun 2010 B2
7816434 Hackbarth et al. Oct 2010 B2
7871649 Modak et al. Jan 2011 B2
7874467 Pardes et al. Jan 2011 B2
7914494 Hiejima Mar 2011 B2
7981475 Takahashi Jul 2011 B2
8034454 Terry Oct 2011 B2
8034455 Wang et al. Oct 2011 B2
8067402 Whiteford et al. Nov 2011 B2
8133423 Tang et al. Mar 2012 B2
8227050 O'Neil Jul 2012 B1
8231602 Anderson Jul 2012 B2
8263102 Labrecque et al. Sep 2012 B2
8268381 Whiteford et al. Sep 2012 B2
8343523 Toreki et al. Jan 2013 B2
8343525 Davis et al. Jan 2013 B2
8353876 Suwito et al. Jan 2013 B2
8357119 Stout et al. Jan 2013 B2
8388583 Stout et al. Mar 2013 B2
8414547 DiFiore et al. Apr 2013 B2
8512294 Ou-Yang et al. Aug 2013 B2
8574171 Nesbitt et al. Nov 2013 B2
8622995 Ziebol et al. Jan 2014 B2
8622996 Ziebol et al. Jan 2014 B2
8691887 Ou-Yang Apr 2014 B2
8728030 Woehr May 2014 B2
8840927 DiTizio et al. Sep 2014 B2
9028425 Burkholz May 2015 B2
9078441 Raad Jul 2015 B2
9138252 Bierman et al. Sep 2015 B2
9259284 Rogers Feb 2016 B2
9750928 Burkholz et al. Sep 2017 B2
10493244 Peterson et al. Dec 2019 B2
20010010016 Modak et al. Jul 2001 A1
20010016589 Modak et al. Aug 2001 A1
20010018095 Shienker et al. Aug 2001 A1
20010020153 Howell Sep 2001 A1
20010032006 Griffin et al. Oct 2001 A1
20010049519 Holman et al. Dec 2001 A1
20010053895 Vaillancourt Dec 2001 A1
20010056133 Montgomery Dec 2001 A1
20020009436 Doyle et al. Jan 2002 A1
20020022660 Jampani et al. Feb 2002 A1
20020028751 Lokkesmoe et al. Mar 2002 A1
20020037260 Budny et al. Mar 2002 A1
20020040092 Siddiqui et al. Apr 2002 A1
20020064858 Yacoby-Zeevi May 2002 A1
20020091424 Biel Jul 2002 A1
20020119111 Kilgour et al. Aug 2002 A1
20020133124 Leinsing et al. Sep 2002 A1
20020144705 Brattesani et al. Oct 2002 A1
20030023208 Osypka et al. Jan 2003 A1
20030060804 Vaillancourt Mar 2003 A1
20030068667 Olson et al. Apr 2003 A1
20030072781 Pelerin Apr 2003 A1
20030105143 Ammendola et al. Jun 2003 A1
20030119932 Al-Akhdar et al. Jun 2003 A1
20030134783 Harshey et al. Jul 2003 A1
20030144362 Utterberg et al. Jul 2003 A1
20030147932 Nun et al. Aug 2003 A1
20030162839 Symington et al. Aug 2003 A1
20030170308 Cleary et al. Sep 2003 A1
20030176848 Gibson et al. Sep 2003 A1
20030206875 Budny et al. Nov 2003 A1
20030215433 Kokai-Kun et al. Nov 2003 A1
20030224032 Read et al. Dec 2003 A1
20040013574 Conway Jan 2004 A1
20040013703 Ralph et al. Jan 2004 A1
20040014864 Milic et al. Jan 2004 A1
20040039349 Modak et al. Feb 2004 A1
20040058829 Hei et al. Mar 2004 A1
20040062592 Shekalim et al. Apr 2004 A1
20040109852 Xu Jun 2004 A1
20040115477 Nesbit Jun 2004 A1
20040132164 Doyle et al. Jul 2004 A1
20040180829 Bassler et al. Sep 2004 A1
20040185296 Mazzanti Sep 2004 A1
20040230162 Tan Nov 2004 A1
20040234475 Lannibois-Drean et al. Nov 2004 A1
20050008671 Van Antwerp Jan 2005 A1
20050048005 Stockel Mar 2005 A1
20050048124 Sarangapani Mar 2005 A1
20050059731 Albrecht et al. Mar 2005 A1
20050080158 Ong et al. Apr 2005 A1
20050100580 Osborne et al. May 2005 A1
20050118239 Sabesan Jun 2005 A1
20050124970 Kunin et al. Jun 2005 A1
20050131356 Ash et al. Jun 2005 A1
20050143286 Singh et al. Jun 2005 A1
20050147525 Bousquet Jul 2005 A1
20050148928 Molina et al. Jul 2005 A1
20050158253 Budney et al. Jul 2005 A1
20050176905 Moon et al. Aug 2005 A1
20050209581 Butts et al. Sep 2005 A1
20050209583 Powers et al. Sep 2005 A1
20050233950 Madhyastha Oct 2005 A1
20050265931 Qian Dec 2005 A1
20060024372 Utterberg et al. Feb 2006 A1
20060051385 Scholz Mar 2006 A1
20060064159 Porter et al. Mar 2006 A1
20060163515 Ruschke Jul 2006 A1
20060165751 Chudzik et al. Jul 2006 A1
20060165903 Mazzanti Jul 2006 A1
20060177477 Ash et al. Aug 2006 A1
20060239954 Sancho Oct 2006 A1
20060258780 Chaussade et al. Nov 2006 A1
20060259012 Propp et al. Nov 2006 A1
20060259032 Nesbitt Nov 2006 A1
20060281663 Asmus Dec 2006 A1
20070000407 Leong Jan 2007 A1
20070083157 Belley et al. Apr 2007 A1
20070083162 O'Reagan et al. Apr 2007 A1
20070093762 Utterberg et al. Apr 2007 A1
20070112112 Kerschner et al. May 2007 A1
20070112146 Falk et al. May 2007 A1
20070129690 Rosenblatt et al. Jun 2007 A1
20070141524 Brennan et al. Jun 2007 A1
20070154621 Raad Jul 2007 A1
20070160547 Duffy et al. Jul 2007 A1
20070166344 Qu et al. Jul 2007 A1
20070202177 Hoang Aug 2007 A1
20070203574 McGrath et al. Aug 2007 A1
20070225179 Schutz et al. Sep 2007 A1
20070233007 Adams Oct 2007 A1
20070275101 Lu et al. Nov 2007 A1
20070281198 Lousenberg Dec 2007 A1
20080026026 Lu et al. Jan 2008 A1
20080027410 Harding et al. Jan 2008 A1
20080033371 Updegraff et al. Feb 2008 A1
20080039796 Nakajima Feb 2008 A1
20080051737 Paul et al. Feb 2008 A1
20080075761 Modak et al. Mar 2008 A1
20080103487 Susumu May 2008 A1
20080108944 Woehr et al. May 2008 A1
20080119789 Kaemmerer May 2008 A1
20080161763 Harding Jul 2008 A1
20080182921 Suh et al. Jul 2008 A1
20080194707 Potter Aug 2008 A1
20080319387 Amisar et al. Dec 2008 A1
20090012220 Yamane et al. Jan 2009 A1
20090036768 Seehusen et al. Feb 2009 A1
20090062766 Howlett et al. Mar 2009 A1
20090101152 Burk et al. Apr 2009 A1
20090110844 Playzer et al. Apr 2009 A1
20090114327 Breunig May 2009 A1
20090117164 Toreki et al. May 2009 A1
20090125118 Gong May 2009 A1
20090157007 McKinnon Jun 2009 A1
20090162530 Nesbit Jun 2009 A1
20090176907 Subramanian et al. Jul 2009 A1
20090188559 Nesbit Jul 2009 A1
20090211909 Nesbit Aug 2009 A1
20090220739 Chougule Sep 2009 A1
20090226541 Scholz et al. Sep 2009 A1
20090281525 Harding et al. Nov 2009 A1
20090299452 Eidenschink et al. Dec 2009 A1
20090317435 Vandesteeg et al. Dec 2009 A1
20090324666 Krongauz et al. Dec 2009 A1
20090324738 Krongauz Dec 2009 A1
20100015200 McClain et al. Jan 2010 A1
20100024648 Breault Feb 2010 A1
20100069854 Okoh et al. Mar 2010 A1
20100106102 Ziebol et al. Apr 2010 A1
20100106103 Ziebol et al. Apr 2010 A1
20100135949 Ou-Yang Jun 2010 A1
20100136209 Ou-Yang et al. Jun 2010 A1
20100137379 Komori et al. Jun 2010 A1
20100137472 Ou-Yang Jun 2010 A1
20100200017 Kerr et al. Aug 2010 A1
20100204648 Stout et al. Aug 2010 A1
20100204675 Woehr et al. Aug 2010 A1
20100222746 Burkholz Sep 2010 A1
20100228178 McGraw Sep 2010 A1
20100249713 Burkholz Sep 2010 A1
20110009831 Burkholz et al. Jan 2011 A1
20110044850 Solomon et al. Feb 2011 A1
20110146680 Conway Jun 2011 A1
20110150958 Davis et al. Jun 2011 A1
20110160662 Stout et al. Jun 2011 A1
20110160663 Stout et al. Jun 2011 A1
20110218529 Garcia et al. Sep 2011 A1
20110301553 Goral et al. Dec 2011 A1
20110319825 Goral et al. Dec 2011 A1
20120016318 Hoang et al. Jan 2012 A1
20120078203 Gaube et al. Mar 2012 A1
20120083750 Sancoucy Apr 2012 A1
20120103448 Hopf et al. May 2012 A1
20120111368 Rahimy et al. May 2012 A1
20120277576 Lui Nov 2012 A1
20120302997 Gardner et al. Nov 2012 A1
20130090607 McKinnon et al. Apr 2013 A1
20130090609 Sonderegger et al. Apr 2013 A1
20130165867 Isaacson et al. Jun 2013 A1
20130165868 Isaacson et al. Jun 2013 A1
20130171030 Ferlic et al. Jul 2013 A1
20130184679 Ziebol et al. Jul 2013 A1
20130196079 Schwalm et al. Aug 2013 A1
20130197485 Gardner et al. Aug 2013 A1
20130204231 Ziebol et al. Aug 2013 A1
20130245568 Kerr Sep 2013 A1
20130274686 Ziebol et al. Oct 2013 A1
20130310764 Burkholz et al. Nov 2013 A1
20130330387 Ou-Yang Dec 2013 A1
20140276433 Woehr Sep 2014 A1
20160008517 Burkholz et al. Jan 2016 A1
20170095596 Petrak et al. Apr 2017 A1
Foreign Referenced Citations (153)
Number Date Country
1331333 Aug 1994 CA
2133053 Mar 1995 CA
2814971 Apr 2012 CA
2905829 Oct 2014 CA
2642540 Nov 2015 CA
2825052 Aug 2016 CA
1187598 Jul 1998 CN
1526771 Sep 2004 CN
1585654 Feb 2005 CN
101353545 Jan 2009 CN
101426539 May 2009 CN
102070983 May 2011 CN
102481391 May 2012 CN
102497894 Jun 2012 CN
103055373 Apr 2013 CN
204684447 Oct 2015 CN
821629 Nov 1951 DE
2104745 Aug 1972 DE
3314640 Nov 1983 DE
3913392 Oct 1990 DE
3913392 Oct 1991 DE
29712676 Nov 1997 DE
202009009602 Dec 2009 DE
102008044296 Jul 2010 DE
0036294 Sep 1981 EP
0070087 Jan 1983 EP
0227230 Jul 1987 EP
0328421 Aug 1989 EP
0338418 Oct 1989 EP
0370997 May 1990 EP
0379271 Jul 1990 EP
0396431 Nov 1990 EP
0414997 Mar 1991 EP
484092 May 1992 EP
0778337 Nov 1997 EP
0992252 Apr 2000 EP
1197242 Apr 2002 EP
1466645 Oct 2004 EP
1679043 Jul 2006 EP
2868722 May 2015 EP
3134161 Feb 2020 EP
S57-501165 Jul 1982 JP
H02-234764 Sep 1990 JP
05277434 Oct 1993 JP
H0747435 Feb 1995 JP
H07051651 Feb 1995 JP
H08-27404 Jan 1996 JP
98182764 Jul 1996 JP
H08209064 Aug 1996 JP
H08311373 Nov 1996 JP
99151262 Jun 1997 JP
H09157548 Jun 1997 JP
H09176677 Jul 1997 JP
99324135 Dec 1997 JP
H10000231 Jan 1998 JP
H10192415 Jul 1998 JP
H11507275 Jun 1999 JP
H11322560 Nov 1999 JP
2000178475 Jun 2000 JP
2000-264803 Sep 2000 JP
2001-072438 Mar 2001 JP
2002510774 Apr 2002 JP
2002-282762 Oct 2002 JP
2003-342402 Dec 2003 JP
2004-043669 Feb 2004 JP
2005-028209 Feb 2005 JP
2005512610 May 2005 JP
2005-515838 Jun 2005 JP
2005-520912 Jul 2005 JP
2006102254 Apr 2006 JP
2007-016096 Jan 2007 JP
2008-533051 Aug 2008 JP
2009-527356 Jul 2009 JP
2009-528360 Aug 2009 JP
2009-544454 Dec 2009 JP
2009542326 Dec 2009 JP
2010-174075 Aug 2010 JP
2010-536836 Dec 2010 JP
2011-528275 Nov 2011 JP
2012-510339 May 2012 JP
2012-510559 May 2012 JP
2012100762 May 2012 JP
2012-532681 Dec 2012 JP
2013-505062 Feb 2013 JP
2013518686 May 2013 JP
2013533005 Aug 2013 JP
2013540486 Nov 2013 JP
2015-519303 Jul 2015 JP
20020066429 Aug 2002 KR
20080039460 May 2008 KR
8200413 Feb 1982 WO
9422522 Oct 1994 WO
9521648 Aug 1995 WO
9616690 Jun 1996 WO
9640359 Dec 1996 WO
9858690 Dec 1998 WO
9858989 Dec 1998 WO
9916498 Apr 1999 WO
9932168 Jul 1999 WO
9934849 Jul 1999 WO
9936490 Jul 1999 WO
9943971 Sep 1999 WO
9944654 Sep 1999 WO
9012171 Mar 2000 WO
0066189 Nov 2000 WO
0074743 Dec 2000 WO
0147592 Jul 2001 WO
0195862 Dec 2001 WO
02051464 Jul 2002 WO
2003041759 May 2003 WO
2004071568 Aug 2004 WO
2004108091 Dec 2004 WO
2005037340 Apr 2005 WO
2006012446 Feb 2006 WO
2006056482 Jun 2006 WO
2006074666 Jul 2006 WO
2006088288 Aug 2006 WO
2006099358 Sep 2006 WO
2006099359 Sep 2006 WO
2006100442 Sep 2006 WO
2007021840 Feb 2007 WO
2007052656 May 2007 WO
2007064835 Jun 2007 WO
2007095576 Aug 2007 WO
2007100653 Sep 2007 WO
2007100776 Sep 2007 WO
2008014438 Jan 2008 WO
2008014447 Jan 2008 WO
2008031601 Mar 2008 WO
2008045761 Apr 2008 WO
2008052790 May 2008 WO
2008128896 Oct 2008 WO
2008132045 Nov 2008 WO
2008152849 Dec 2008 WO
2009012336 Jan 2009 WO
2009055949 May 2009 WO
2009070227 Jun 2009 WO
2009114833 Sep 2009 WO
2010034470 Apr 2010 WO
2010093791 Aug 2010 WO
2011005951 Jan 2011 WO
2011034675 Mar 2011 WO
2011048204 Apr 2011 WO
2011118680 Sep 2011 WO
2012036916 Mar 2012 WO
2013003373 Jan 2013 WO
2013009998 Jan 2013 WO
2013134421 Sep 2013 WO
2013151860 Oct 2013 WO
2014031774 Feb 2014 WO
2014052283 Apr 2014 WO
2015133281 Sep 2015 WO
2015137098 Sep 2015 WO
Non-Patent Literature Citations (13)
Entry
Gama Healthcare, Clinell Alcoholic 2% Chlorhexidine, http//www.gamahealthcare.com/clinellaca2c.html, pp. 1-3, Nov. 7, 2008.
Enluria, ChloraPrep, http://enluria.com/products/cloraPrep-product.html, pp. 1-3, Oct. 21, 2008.
Sage Products, Inc , Address Multi-Drug Reistant Organism on the Skin with Early Preop Prep, http://www.sageproducts.com/products/ssi-prevention.cfm, 1 page, Oct. 31, 2008.
Sage Products, Inc., Preoperative Skin Preparation and Preoperative Oral Care for the Short-Term Ventilated Patient, http://www.sageproducts.com/products/ssi-vap-prevention.cfm, 1 page, Oct. 2008.
Sage Products, Inc., Preoperative Skin Preparation for the Surgical Patient, http://www.sageproducts.com/products/skin-prep.cfm, 1 page, Oct. 31, 2008.
ComfortCoat Hydrophilic Coating, DSM in Medical, http://www.dsm.com/en_US/medical/public/home/pages/product-coating-comfortcoat.jsp. Updated Jan. 11, 2013, Printed Apr. 22, 2013.
Lubricent—Lubricious Hydrophillic Coatings for Medical Devices, Harland Medical Systems, http://www.harlandmedical.com/index.php/materials/lubricent.html, pp. 1-2, Printed Apr. 22, 2013.
UV & EB Cure, Xiper Innovations, Inc., http://xiperinnovations.com/uv_eb_cure, Printed Apr. 22, 2013.
Gerald McDonnell and A. Denver Russell, Antiseptics and Disinfectants: Activity, Action and Resistance, Clinical Microbiology Reviews, vol. 12, Jan. 1999, p. 147-179.
Cabot Corporation, “Using Silicas and Aluminas in Coatins,” www.cabot-corp.com/Silicas-And-Aluminas/Coatings, downloaded from the internet on Apr. 26, 2011.
Anusavice KJ, Zhang N-Z, Shen C. Controlled Release of Chlorhexidine from UDMA-TEGDMA Resin, Journal of dental research, 2006,85(10); 950-954.
Ciba Irgacure 500 data sheet from Ciba Specialty Chamicals, online, retrieved on [Dec. 13, 2015]. Retrieved from internet <URL://http://www.conquimica.com/wp-content/uploads/2015/06/ft_irgacure_500.pdf.
Elson Silva, PhD, “Respecting Hydrology Science in the Patenting System,” pp. 1-7, Jan. 13, 2011.
Related Publications (1)
Number Date Country
20190344065 A1 Nov 2019 US
Continuations (1)
Number Date Country
Parent 14260027 Apr 2014 US
Child 16450670 US